News & Insights

SolentimNews & Insights
Insights matthews

Clonal Derivation in Biopharmaceutical Cell Line Development – a Regulatory Perspective

19th November 2019: Early last month saw publication of the latest perspectives from the FDA in a paper entitled: Considering “clonality”: A regulatory perspective on the importance of the clonal derivation of mammalian cell banks in biopharmaceutical development authored by Joel Welch and Sarah Arden (USFDA). Key Points As a major supplier of technologies for …

Read more Clonal Derivation in Biopharmaceutical Cell Line Development – a Regulatory Perspective

Insights sciadseo

Proof of clonality and its importance in stable cell line development

What is clonality and why is it important Clonality is a crucial step in stable cell line development (CLD) for biotherapeutic workflows and one closely monitored by the medicines’ regulators. Their questions lead to two possible conclusions about how they view the importance of clonality1: Assurance of “clonality” of stable production cell lines is of …

Read more Proof of clonality and its importance in stable cell line development

Insights matthews

Continuous innovation of host cell lines for cell line development

Author: Ian Taylor, Chief Commercial Officer, Solentim At last week’s Oxford Global Conference in London, a couple of talks stood out for me on innovations for improving host cell lines in cell line development. First up was Mario Pereira from Horizon Discovery who nicely explained the history of the Company’s HD-BIOP3 GS null knockout for …

Read more Continuous innovation of host cell lines for cell line development

Insights matthews

Eliminating enrichment steps in cell line development – reduce cell screening from 5000 to 200 clones per project

Coffee Morning Chat with Ferenc Boldog (ATUM) and Ian Taylor (Solentim): An expert discussion on the evolution of cell line development to negate the need for enrichment In the time since my previous blog following the ESACT conference in May, in which I discussed fluorescence screening of clones in cell line development, I have been …

Read more Eliminating enrichment steps in cell line development – reduce cell screening from 5000 to 200 clones per project

Corporate sciadseo

Mark Stockdale joins Solentim in new “Amalgamator of Business and Biology” position

Bournemouth, UK, 8th October 2019: Solentim, the global leader in cell line development instrumentation, is delighted to announce that Mark Stockdale is starting at Solentim in a brand-new role as Amalgamator of Business and Biology. Mark has previously spent 10 years at Horizon Discovery, most recently working within the Applied Products Division as an R&D …

Read more Mark Stockdale joins Solentim in new “Amalgamator of Business and Biology” position

Corporate sciadseo

Dr Mark Truesdale joins Solentim as new Chief Marketing Officer

Solentim, the global leader in cell line development (CLD) instrumentation, is delighted to announce that Dr Mark Truesdale will join the Company as the new Chief Marketing Officer, effective immediately. Mark brings with him a wealth of experience, most recently seven years at Thermo Fisher Scientific, during which time he held the position of Senior …

Read more Dr Mark Truesdale joins Solentim as new Chief Marketing Officer